Illumina (ILMN) vs Personalis (PSNL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Illumina (ILMN) has outperformed Personalis (PSNL) over the past year, gaining 170.6% versus a gain of 85.0%. Over five years, PSNL leads with a -19.5% price change compared with -33.7% for ILMN. Illumina is the larger company by market cap ($39.95 billion vs $1.72 billion), about 23.3 times the size.
Illumina converts more of its revenue into profit, with a net margin of 19.6% versus -116.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ILMN | PSNL |
|---|---|---|
| Share price | $264.57 | $16.06 |
| Market cap | $39.95B | $1.72B |
| 1-day change | -1.19% | +0.37% |
| YTD return | +101.72% | +101.76% |
| 1-year return | +170.58% | +85.02% |
| 5-year return | -33.65% | -19.46% |
| P/E ratio (TTM) | 49.36 | — |
| Forward P/E | 43.24 | — |
| EPS (TTM) | $5.36 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $4.34B | $69.65M |
| Revenue growth (YoY) | -0.66% | -17.69% |
| Net income (latest FY) | $850.00M | $-81.27M |
| Gross margin | 66.08% | 22.65% |
| Operating margin | 18.58% | -126.43% |
| Net margin | 19.57% | -116.69% |
| 52-week high | $309.35 | $18.89 |
| 52-week low | $88.00 | $4.96 |
| Distance from 52-week high | -14.48% | -14.98% |
| Analyst consensus | buy | hold |
| Avg. price target upside | -12.25% | -5.54% |
| Average volume | 2.69M | 3.59M |
| Shares outstanding | 151.00M | 106.80M |
| Employees | 8,600 | 259 |
| Sector | Healthcare | Healthcare |
| Industry | Diagnostics & Research | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Illumina is about 23.3 times larger than Personalis by market value ($39.95B vs $1.72B).
- ILMN has outperformed PSNL by 85.6 percentage points over the past year.
- Illumina is more profitable, keeping 19.6 cents of every revenue dollar as net income versus -116.7 cents for Personalis.
- Illumina grew revenue faster in its latest fiscal year (-0.66% vs -17.69%).
About Illumina
ILMN stock →Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.
Healthcare · Diagnostics & Research · 8,600 employees
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Healthcare · Diagnostics & Research · 259 employees
ILMN vs PSNL FAQ
Which is bigger, Illumina or Personalis?
Illumina (ILMN) is larger, with a market capitalization of $39.95B compared with $1.72B for Personalis (PSNL).
Which stock has performed better over the past year, ILMN or PSNL?
ILMN returned +170.58% over the past 12 months, compared with +85.02% for PSNL (price return, excluding dividends). Past performance does not predict future results.
Are Illumina and Personalis in the same industry?
Yes. Both are classified in the Diagnostics & Research industry within the Healthcare sector.